All In Biotech

Drug Trial Radar · NCT05590585

Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial

An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis

Last checked: Nov 20, 2026Latest source record: May 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

124

Actual

Start

Jan 11, 2023

Primary completion

Nov 14, 2024

Study completion Nov 14, 2024

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
Collaborators
Sanofi
First posted
Oct 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is focused on skin of color participants who have moderate-to-severe atopic dermatitis. Atopic dermatitis, also referred to as eczema, is a condition that causes the skin to become itchy, dry, and cracked. From the previous studies on the study drug, it is seen that the study drug has an acceptable safety and effectiveness in participants with atopic dermatitis. The aim of this study is to get additional information on the safety and effectiveness of the study drug, particularly the information on aspects of atopic dermatitis in skin of color participants. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in your blood at different times * How much the study drug improves quality of life and mental health

Conditions

  • Moderate-to-Severe Atopic Dermatitis
  • Atopic Eczema

Interventions

  • dupilumabDrug

    Administered by subcutaneous (SC) injection once every 2 weeks (Q2W) following a loading dose

  • Topical emollient (moisturizer)Other

    Moisturizer should be applied twice daily, as per physician's recommendation, as defined in protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With ≥75% Reduction From Baseline in Eczema Area and Severity Index (EASI) Score (EASI-75)Time frame: Week 24

Locations

30 sites in 1 country. Site status is shown where the registry gives one.

  • Total Skin & Beauty Dermatology Center

    Birmingham, Alabama

  • The University Of Alabama At Birmingham

    Birmingham, Alabama

  • C2 Research Center, LLC

    Montgomery, Alabama

  • Center for Dermatology Clinical Research, inc.

    Fremont, California

  • UCSD/ Rady Children's Hospital

    San Diego, California

  • UCSF

    San Francisco, California

  • SF Research Institute

    San Francisco, California

  • University of Miami Miller School of Medicine

    Miami, Florida

  • Skin and Cancer Associates, LLP

    Miami, Florida

  • Century Research LLC

    Miami, Florida

  • Advanced Medical Research PC

    Atlanta, Georgia

  • Atlanta Biomedical Clinical Research LLC

    Atlanta, Georgia

  • Northwestern Memorial Hospital

    Chicago, Illinois

  • Callender Dermatology and Cosmetic Center

    Glenn Dale, Maryland

  • Dermatology and Skin Cancer Specialists, LLC dba US Dermatology Partners

    Rockville, Maryland

  • Wayne State University Physician Group Dermatology

    Dearborn, Michigan

  • Revival Research Institute , LLC

    Troy, Michigan

  • Washington University School of Medicine

    St Louis, Missouri

  • Rao Dermatology

    Atlantic Highlands, New Jersey

  • SUNY Downstate Medical Center

    Brooklyn, New York

  • NYC Health + Hospital , Elmhurst Hospital Center

    Elmhurst, New York

  • Markowitz Medical

    New York, New York

  • Philip Fried, MD PLLC

    The Bronx, New York

  • Duke University Medical Center

    Durham, North Carolina

  • Oregon Health & Science University

    Portland, Oregon

  • National Allergy and Asthma Research, LLC.

    North Charleston, South Carolina

  • Center for Clinical Studies, LTD.LLP

    Houston, Texas

  • Heights Dermatology & Aesthetic Center - Heights Location

    Houston, Texas

  • RFSA Dermatology

    San Antonio, Texas

  • Texas Dermatology and Laser Specialists

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.